» Articles » PMID: 34577178

A Novel LC-MS/MS-Based Method for the Diagnosis of ADA2 Deficiency from Dried Plasma Spot

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2021 Sep 28
PMID 34577178
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine Deaminase 2 Deficiency (DADA2) (OMIM: 607575) is a monogenic, autoinflammatory disease caused by the loss of functional homozygous or heterozygous mutations in the ADA 2 gene (previously CECR1, Cat Eye Syndrome Chromosome Region 1). A timely diagnosis is crucial to start Anti-TNF therapies that are efficacious in controlling the disease. The confirmation of DADA2 is based on DNA sequencing and enzymatic assay. It is, thus, very important to have robust and reliable assays that can be rapidly utilized in specialized laboratories that can centralize samples from other centers. In this paper, we show a novel enzymatic assay based on liquid chromatography-tandem mass spectrometry that allows the accurate determination of the ADA2 enzyme activity starting from very small amounts of plasma spotted on filter paper (dried plasma spot). The method allows significantly distinguishing healthy controls from affected patients and carriers and could be of help in implementing the diagnostic workflow of DADA2.

Citing Articles

Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities.

Bulte D, Barzaghi F, Mesa-Nunez C, Rigamonti C, Basso-Ricci L, Visconti C J Allergy Clin Immunol. 2024; 155(2):616-627.e8.

PMID: 39284370 PMC: 11804788. DOI: 10.1016/j.jaci.2024.09.007.


A Narrative Review of the Neurological Manifestations of Human Adenosine Deaminase 2 Deficiency.

Dzhus M, Ehlers L, Wouters M, Jansen K, Schrijvers R, De Somer L J Clin Immunol. 2023; 43(8):1916-1926.

PMID: 37548813 PMC: 10661818. DOI: 10.1007/s10875-023-01555-y.


Biological Fluid Microsampling for Therapeutic Drug Monitoring: A Narrative Review.

Cafaro A, Conti M, Pigliasco F, Barco S, Bandettini R, Cangemi G Biomedicines. 2023; 11(7).

PMID: 37509602 PMC: 10377272. DOI: 10.3390/biomedicines11071962.


Case Report: Susceptibility to viral infections and secondary hemophagocytic lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of adenosine deaminase 2 deficiency.

Drago E, Garbarino F, Signa S, Grossi A, Schena F, Penco F Front Immunol. 2022; 13:937108.

PMID: 36159847 PMC: 9503826. DOI: 10.3389/fimmu.2022.937108.


Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity.

Signa S, Bertoni A, Penco F, Caorsi R, Cafaro A, Cangemi G Front Immunol. 2022; 13:935957.

PMID: 35898506 PMC: 9309328. DOI: 10.3389/fimmu.2022.935957.


References
1.
Caorsi R, Penco F, Schena F, Gattorno M . Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 2016; 14(1):51. PMC: 5015262. DOI: 10.1186/s12969-016-0111-7. View

2.
Schena F, Penco F, Volpi S, Pastorino C, Caorsi R, Kalli F . Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients. Eur J Immunol. 2020; 51(1):206-219. DOI: 10.1002/eji.202048549. View

3.
Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield M, Kelly S . Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency. J Pediatr. 2016; 177:316-320. DOI: 10.1016/j.jpeds.2016.06.058. View

4.
Ito M, Nihira H, Izawa K, Yasumi T, Nishikomori R, Iwaki-Egawa S . Enzyme activity in dried blood spot as a diagnostic tool for adenosine deaminase 2 deficiency. Anal Biochem. 2021; 628:114292. DOI: 10.1016/j.ab.2021.114292. View

5.
Zhou Q, Yang D, Ombrello A, Zavialov A, Toro C, Zavialov A . Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014; 370(10):911-20. PMC: 4193683. DOI: 10.1056/NEJMoa1307361. View